https://www.panabee.com/news/champions-oncology-earnings-q3-2026-report
Champions Oncology Earnings Q3 2026 - Report | CSBR News & Analysis
Champions Oncology reported 9% revenue growth to $15.2 million, driven by a strategic pivot toward high-margin data licensing. However, rising sales and...
champions oncologynews analysisearningsreportcsbr
https://informadrid.com/champions-oncology-nombra-a-brian-alexander-para-su-consejo-de-administracion/
Champions Oncology nombra a Brian Alexander para su Consejo de Administración - DIARIO INFORMADRID
Mar 30, 2026 - El nombramiento subraya el enfoque de Champions en aprovechar datos clínicamente relevantes para impulsar la I+D oncológica de próxima generación
champions oncologybrian alexandernombraparaconsejo
https://shortsell.net/company/CSBR-Champions_Oncology/
Champions Oncology - Shortsell.net
Champions Oncology has been a target of short sellers for a while. The current short interest of 0.49% is roughly at the average of the last 12 months (0.56%).
champions oncology
https://www.championsoncology.com/cell-lines/ov-90?hsLang=en
OV-90 | CDX Model | Champions Oncology
Accelerate your oncology drug discovery with Champions Oncology's validated cell line-derived xenograft models. Learn more.
champions oncologycdxmodel
https://zlk.com/tickers/csbr/sec-filings
CSBR CHAMPIONS ONCOLOGY, INC. SEC Filings | Levi & Korsinsky, LLP | Securities Class Action...
securities class actionchampions oncologycsbrincfilings